Pacira BioSciences, Inc. (PCRX) Stock Forecast & Price Target
Pacira BioSciences, Inc. · NASDAQ
$25.89-0.46 (-1.75%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Pacira BioSciences, Inc, 3 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $25.00 to $38.00, a moderate spread. The average target of $29.80 sits 15% above the current $25.89. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.84 next quarter toward $3.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy360%
Hold240%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Pacira BioSciences, Inc.
As of Sep, 3 of 5 firms rate PCRX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PCRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.84
Range $0.71 – $0.93 · 7 analysts · +48% YoY
Next period, 7 analysts expect Pacira BioSciences, Inc. to earn $0.84 a share (range $0.71 – $0.93), versus $0.57 a year earlier. Full-year consensus is $2.88, growing to $3.45 the year after.
REVENUE · NEXT QUARTER
$201.4M
Range $197.4M – $204.2M · 7 analysts · +2% YoY
Revenue is expected to reach $201.4M (range $197.4M – $204.2M), +2.3% year-over-year. Full-year consensus is $753.0M, rising to $788.2M next year.
Top analysts covering Pacira BioSciences, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PCRX.
#1
Serge Belanger
Needham · Rank #105
Buy
$33.00+27.5% to target
Overall win rate
48%
+ Follow
#2
Oren Livnat
HC Wainwright & Co. · Rank #170
Buy
$65.00+151.1% to target
Overall win rate
54%
+ Follow
#3
Balaji Prasad
Barclays · Rank #178
Buy
$24.00-7.3% to target
Overall win rate
44%
+ Follow
#4
DM
Douglas Miehm
RBC Capital · Rank #190
Hold
$25.00-3.4% to target
Overall win rate
43%
+ Follow
#5
Gregory Renza
RBC Capital · Rank #213
Hold
$18.00-30.5% to target
Overall win rate
34%
+ Follow
PCRX stock forecast FAQ
What is PCRX's average 12-month price target?+
The 5 analysts with a live target average $29.80 for Pacira BioSciences, Inc. over the next 12 months, ranging from a $38.00 high to a $25.00 low.
Is PCRX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 3 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PCRX?+
The Street-high target is $38.00 (HC Wainwright & Co.), and the Street-low is $25.00 (RBC Capital). The average of all 5 active targets is $29.80.
How many Wall Street analysts cover PCRX?+
5 analysts have an active rating on Pacira BioSciences, Inc., and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering PCRX?+
Among analysts who currently cover PCRX, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #105). Their current call is Buy with a $33.00 target.
What is Pacira BioSciences, Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.84 per share (range $0.71 – $0.93) across 7 analysts. Full-year EPS is projected at $2.88, rising to $3.45 the following year.
How much revenue is Pacira BioSciences, Inc. expected to report next quarter?+
Consensus revenue is $201.4M (range $197.4M – $204.2M). Full-year revenue is projected at $753.0M, growing to $788.2M next year.
Have analysts been upgrading or downgrading PCRX lately?+
As of Sep, 3 of 5 firms rate PCRX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PCRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
